Rima Jubran, MD

Professor of Clinical Pediatrics (Educational Scholar)

Designated Institute Official for CHLA

Image of Rima Jubran, MD
Is this your profile? Click to edit

Overview

Rima Fuad Jubran, MD, MPH, MACM is the Designated Institutional Official and Director of Graduate Medical Education at Children’s Hospital Los Angeles, where she oversees all physician training programs. In addition, Dr. Jubran is a pediatric oncologist who cares for patients with retinoblastoma, histiocytic disorders and solid tumors. She received her medical degree from Case Western Reserve University School of Medicine, Cleveland, Ohio, and her Master of Public Health at George Washington University, Washington, D.C. Following her residency at Rainbow Babies and Children’s Hospital in Cleveland, she completed a fellowship in pediatric hematology/oncology at Children’s National Medical Center, Washington, D.C. Dr. Jubran is a member of the retinoblastoma committee of the national Children’s Oncology Group and one of the founding members of the North American Consortium for Histiocytic Disorders. Her investigations focus on retinoblastoma and Langerhans cell histiocytosis. A frequent lecturer and author, she is an active member of the international Histiocytosis Society. She serves on the Board of the Kevin Cordasco Foundation and the Histiocyte Association.

Awards

  • Drexel University: The Hedwig van Ameringen Executive Leadership in Academic Medicine, 2020
     – 2021
  • University of Southern California: USC Academic Senate Faculty Service Award, 2023
  • Children’s Hospital Los Angeles: Walter Laug Distinguished Teaching Award, 2011
  • Keck School of Medicine of USC: Outstanding Teaching in Professionalism in the Practice of Medicine, 2012
  • Keck School of Medicine of USC: Outstanding Teaching in Professionalism in the Practice of Medicine, 2015

Education and Training

  • Case Western Reserve University School of Medicine, Cleveland, OH — MD — 05/1992 — Medicine
  • George Washington University, Washington, DC — MPH — 05/1999 — Public Health Policy
  • University of Southern California, Los Angeles, CA — MACM — 05/2012 — Academic Medicine

Publications

  • Clofarabine for relapsed/refractory LCH and non-LC histiocytosis. Blood Adv. 2026 07 28; 10(14):5087-5096.. View in PubMed
  • Saving the Eye, Counting the Cost: Rethinking Treatment Burden in Unilateral Retinoblastoma. Clin Exp Ophthalmol. 2026 Mar; 54(2):183-185.. View in PubMed
  • Prospective implementation of an aqueous humor liquid biopsy platform informs clinical diagnosis and management of retinoblastoma and other intraocular lesions. NPJ Precis Oncol. 2026 Jan 12; 10(1):53.. View in PubMed
  • Diffuse infiltrating retinoblastoma: a multicentre, international, data-sharing study. Br J Ophthalmol. 2025 Nov 20; 109(12):1409-1416.. View in PubMed
  • The use of aqueous humor cfDNA for low-pass whole genome sequencing as a clinical test to identify intraocular retinoblastoma recurrence. ScienceBank. 2025; 2025.. View in PubMed
  • Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures. Cancer. 2024 Jul 15; 130(14):2416-2439.. View in PubMed
  • A multi-institutional feasibility study of intra-arterial chemotherapy in children with retinoblastoma. A Children’s Oncology Group study (COG ARET12P1). Pediatr Blood Cancer. 2024 Jan; 71(1):e30718.. View in PubMed
  • Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children’s Oncology Group Trial (ARET0321). J Clin Oncol. 2022 11 20; 40(33):3839-3847.. View in PubMed
  • Metastatic Death Based on Presenting Features and Treatment for Advanced Intraocular Retinoblastoma: A Multicenter Registry-Based Study. Ophthalmology. 2022 08; 129(8):933-945.. View in PubMed
  • High-risk Pathologic Features Based on Presenting Findings in Advanced Intraocular Retinoblastoma: A Multicenter, International Data-Sharing American Joint Committee on Cancer Study. Ophthalmology. 2022 08; 129(8):923-932.. View in PubMed